Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis

Bhandari, Shruti; Kumar, Rohit; Tripathi, Prashant; Chan, Abigail; Mudra, Sarah; Redman, Rebecca

doi:10.1007/s12032-019-1315-8

Cited by 15 publications

(16 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Se describe peor pronóstico cuando el mecanismo fisiopatológico que la produce está ligado al aumento en los niveles de proteína relacionada a la hormona paratiroidea (PTHrP) (14). Estudios previos informan mortalidad del 50 % de los casos al cabo de 30 días desde el diagnóstico de hipercalcemia (2,11,13). En un estudio retrospectivo de 126 pacientes con hipercalcemia maligna y enfermedad refractaria a la quimioterapia, la mediana de supervivencia fue de 1 mes, con un 75 % de mortalidad a los 3 meses; en aquellos a quienes el tratamiento anticancerígeno estuvo disponible, la mediana de supervivencia fue de cuatro meses y otro análisis retrospectivo de casi 8,000 pacientes demostró una supervivencia de 12 meses de solo el 25 % (4).…”

Section: Pronósticounclassified

Actualización: Fisiopatología, Diagnóstico y Manejo de la Hipercalcemia Maligna

Pereira

Chacón

2020

View full text Add to dashboard Cite

Resumen La hipercalcemia maligna es una complicación metabólica común de algunos tumores en estadios avanzados y se define por un valor de calcio sérico mayor a 10.5 mg/dl. Se encuentra principalmente en pacientes con cáncer de mama, pulmón, carcinoma renal, carcinoma de células escamosas de cualquier órgano y neoplasias sanguíneas, sin embargo; puede estar presente en casi cualquier tipo de cáncer. La hipercalcemia maligna humoral es el principal mecanismo fisiopatológico de la hipercalcemia maligna, no obstante también puede asociarse a metástasis osteolíticas y con menos frecuencia a producción ectópica de calcitriol y hormona paratiroidea. La hipercalcemia maligna se clasifica en leve con valores de calcio sérico entre 10.5-11.9 mg/dl, moderada de 12-13.9 mg/dl y severa > a 14 mg/dl; la hipercalcemia leve suele ser asintomática mientras que en la formas moderada y severa se asocian con una presentación clínica variada que van desde síntomas gastrointestinales, neurológicos hasta aquellos asociados con hipovolemia. Respecto al tratamiento este se debe enfocar en la fisiología del trastorno y se recomienda la hidratación agresiva, el uso de medicamentos como calcitonina, bifosfonatos o denosumab y en aquellos casos necesarios diuréticos, glucocorticoides y diálisis. El pronóstico de los pacientes con hipercalcemia maligna es pobre y se asocia con altas tasas de mortalidad.

show abstract

Section: Pronósticounclassified

Actualización: Fisiopatología, Diagnóstico y Manejo de la Hipercalcemia Maligna

Pereira

Chacón

2020

View full text Add to dashboard Cite

show abstract

“…Although mild hypercalcemia can be asymptomatic, moderate and severe hypercalcemia can be associated with a wide range of symptoms from polyuria, polydipsia, dehydration, nephrolithiasis, and muscle weakness all the way to renal failure, lethargy, coma, and cardiac arrest (4). Although not very common, HCM is associated with a longer hospital stay and greater mortality risk when compared to cancer patients without HCM (7). In fact, 50% of patients with HCM may die within a month (7,8).…”

Section: Introductionmentioning

confidence: 99%

“…Although not very common, HCM is associated with a longer hospital stay and greater mortality risk when compared to cancer patients without HCM (7). In fact, 50% of patients with HCM may die within a month (7,8). Therefore, treatment is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

Patients’ values and other decisional factors regarding treatment of hypercalcemia of malignancy: A Systematic Review Protocol

Bassatne

Rahme

Piggott

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Hypercalcemia of malignancy is the second most common cause of hypercalcemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with bisphosphonates, denosumab, glucocorticoids, and calcimimetics, as well as conventional therapy with hydration and possibly calcitonin. While guidelines have previously considered treatment effects, no guideline has yet considered a range of contextual factors impacting recommendations for the management. Objective: The aim of this study is to summarize the available evidence on important decisional factors for the development of guidelines for the treatment of hypercalcemia of malignancy. These include patient’s values and preferences, cost, acceptability, feasibility, and equity. Methods/Design: This is a systematic review of observational studies, case series, trials, reviews and qualitative studies involving treatment of adult patients with hypercalcemia of malignancy. We developed and executed two independent search strategies using five databases: Pubmed, Medline (OVID), Embase.com, CINAHL (EBSCO) and Cochrane, and reviewed their combined output. Two reviewers screened titles and abstracts and full texts and will implement data abstraction from relevant studies independently and in duplicate. The outcomes of interest are the decisional factors that influence drug selection, with possible subgroup analyses by drug class or etiology of hypercalcemia of malignancy. We will present the data collected in a narrative and thematic approach. Discussion: This systematic review will identify important treatment decisional factors, and will assist guidelines panels, physicians and patients to decide on therapeutic options based on the current evidence.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In fact, 50% of patients with HCM may die within a month (7,8). Therefore, treatment is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

Patients’ values and other decisional factors regarding treatment of hypercalcemia of malignancy: A Systematic Review Protocol

Bassatne

Rahme

Piggott

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Hypercalcemia of malignancy is the second most common cause of hypercalcemia and is associated with significant morbidity and mortality. Several treatment options are available including pharmacological therapy with bisphosphonates, denosumab, glucocorticoids, and calcimimetics, as well as conventional therapy with hydration and possibly calcitonin. While guidelines have previously considered treatment effects, no guideline has yet considered a range of contextual factors impacting recommendations for the management. Objective The aim of this study is to summarize the available evidence on important decisional factors for the development of guidelines for the treatment of hypercalcemia of malignancy. These include patient’s values and preferences, cost, acceptability, feasibility, and equity. Methods/Design: This is a systematic review of observational studies, case series, trials, reviews and qualitative studies involving treatment of adult patients with hypercalcemia of malignancy. We developed and executed two independent search strategies using five databases: Pubmed, Medline (OVID), Embase.com, CINAHL (EBSCO) and Cochrane, and reviewed their combined output. Two reviewers screened titles and abstracts and full texts and will implement data abstraction from relevant studies independently and in duplicate. The outcomes of interest are the decisional factors that influence drug selection, with possible subgroup analyses by drug class or etiology of hypercalcemia of malignancy. We will present the data collected in a narrative and thematic approach. Discussion This systematic review will identify important treatment decisional factors, and will assist guidelines panels, physicians and patients to decide on therapeutic options based on the current evidence.

show abstract

Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis

Cited by 15 publications

References 9 publications

Actualización: Fisiopatología, Diagnóstico y Manejo de la Hipercalcemia Maligna

Actualización: Fisiopatología, Diagnóstico y Manejo de la Hipercalcemia Maligna

Patients’ values and other decisional factors regarding treatment of hypercalcemia of malignancy: A Systematic Review Protocol

Patients’ values and other decisional factors regarding treatment of hypercalcemia of malignancy: A Systematic Review Protocol

Contact Info

Product

Resources

About